ICLN: Renewable Energy Set For Growth Before Tax Credits Expire — Neutral
ICLN Seeking Alpha — September 03, 2025ICLN offers diversified exposure to global clean energy producers, with a focus on wind, solar, and geothermal sectors. U.S. policy changes may accelerate renewable project growth through 2027, but tax credit phase-outs pose longer-term risks to the sector's momentum. ICLN's international diversification and top holdings like First Solar and Vestas position it well for near-term growth, despite historical underperformance.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sable Offshore — Neutral
SOC GlobeNewsWire — September 03, 2025Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sable Offshore To Contact Him Directly To Discuss Their Options
Tractor Supply Company (TSCO) Presents At Goldman Sachs 32nd Annual Global Retailing Conference 2025 Transcript — Neutral
TSCO Seeking Alpha — September 03, 2025Tractor Supply Company (NASDAQ:TSCO ) Goldman Sachs 32nd Annual Global Retailing Conference 2025 September 3, 2025 9:35 AM EDT Company Participants Harry Lawton - President, CEO & Director Kurt Barton - Executive VP, CFO & Treasurer Conference Call Participants Katharine McShane - Goldman Sachs Group, Inc., Research Division Presentation Katharine McShane MD & Retail Analyst Okay. Good morning.
The Best Home Run Growth Stocks To Buy Today — Positive
ISRG NVDA TSM 24/7 Wall Street — September 03, 2025
Disney to pay $10 million to settle FTC complaint over collection of children's personal data on YouTube — Negative
DIS CNBC — September 03, 2025The Walt Disney Company will pay $10 million to settle Federal Trade Commission allegations that it enabled the unlawful collection of children's personal data on YouTube. The FTC claimed the company allowed personal data to be collected from children who viewed kid-directed videos on YouTube without notifying parents or obtaining their consent.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PubMatic — Neutral
PUBM GlobeNewsWire — September 03, 2025Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PubMatic To Contact Him Directly To Discuss Their Options
5 Soft Drink Stocks Battling for Relevance Amid Consumer Taste Shift — Neutral
KDP KO MNST PEP ZVIA Zacks Investment Research — September 03, 2025Beverages - Soft Drinks industry players face cost & tariff headwinds, while health-driven demand, digital growth & innovation open fresh growth avenues. Let us see if top players like KO, PEP, MNST, KDP, and ZVIA can sustain relevance in a rapidly evolving market.
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride — Positive
IONS Zacks Investment Research — September 03, 2025Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
How Will Home Depot Balance Debt, Capex and Shareholder Payouts? — Positive
HD Zacks Investment Research — September 03, 2025HD juggles capex, dividends and debt reduction while pausing buybacks amid the integration of SRS and the pending GMS deal.
CRM Earnings: Margin Story Crucial for Continuing Software Rebound — Positive
CRM Schwab Network — September 03, 2025Melissa Otto believes the key to a Salesforce (CRM) earnings win lies in the margins. She believes capitalizing on efficiency and reducing costs will open a wider runway for Salesforce's A.I.
PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies — Neutral
COYA GlobeNewsWire — September 03, 2025Q&A Highlights FDA IND Clearance, Partnerships, and 2025 Milestones Across ALS and Neurodegeneration Programs NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Arun Swaminathan, Chief Executive Officer of Coya Therapeutics, Inc. (“Coya” or the “Company”) (NASDAQ: COYA), a clinical-stage biotechnology company developing Treg-modulating therapies to address ALS and other neurodegenerative diseases.
Marvell Technology, Inc. (MRVL) Presents At Citi's 2025 Global Technology, Media And Telecommunications Conference Transcript — Neutral
MRVL Seeking Alpha — September 03, 2025Marvell Technology, Inc. (NASDAQ:MRVL ) Citi's 2025 Global Technology, Media and Telecommunications Conference September 3, 2025 9:30 AM EDT Company Participants Matthew Murphy - CEO & Chairman Willem Meintjes - Executive VP & CFO Conference Call Participants Atif Malik - Citigroup Inc., Research Division Presentation Atif Malik Director and Semiconductor Capital Equipment & Specialty Semiconductor Analyst My name is Atif Malik. I cover U.S. semiconductors, semiconductor equipment and networking equipment stocks at Citi.
Palantir's recent share price pullback offers a compelling buying opportunity, as fundamentals remain strong and EPS revisions are highly bullish. Aggressive EPS growth, robust Q2 results, and expanding international partnerships reinforce Palantir's first-mover advantage in the AI software market. Traditional valuation metrics don't apply to disruptors like Palantir; rapid P/E compression and sustained 20%+ EPS CAGR are achievable given fundamental strength.
Colgate-Palmolive Company (CL) Presents At Barclays 18th Annual Global Consumer Staples Conference 2025 Transcript — Neutral
CL Seeking Alpha — September 03, 2025Colgate-Palmolive Company (NYSE:CL ) Barclays 18th Annual Global Consumer Staples Conference 2025 September 3, 2025 9:00 AM EDT Company Participants Noel Wallace - Chairman, CEO & President Conference Call Participants Lauren Lieberman - Barclays Bank PLC, Research Division Presentation Lauren Lieberman MD & Senior Research Analyst Okay. We're going to get started.
Enbridge Nears 52-Week High Mark: Should Investors Bet on the Stock? — Positive
ENB Zacks Investment Research — September 03, 2025ENB rides stable cash flows, dividend strength and data center demand to near its 52-week high, drawing investor attention.
Gold's Record Surge Above $3,500: ETFs to Consider — Positive
GLD Zacks Investment Research — September 03, 2025Gold soars past $3,500, up 41% in a year, as Fed rate cut bets, safe-haven demand and central bank buying fuel the rally.
3 Stocks to Consider From the Thriving Foreign Banks Industry — Positive
BCS HSBC UBS Zacks Investment Research — September 03, 2025The Zacks Foreign Bank stocks like HSBC, UBS and BCS look poised to benefit from core business focus and low rates despite global economic headwinds.
SCWorx Corp. Appoints New Chief Technology Officer to Accelerate Innovation in Healthcare Data Solutions — Neutral
WORX GlobeNewsWire — September 03, 2025Tampa, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX), a leading provider of data management and software solutions for the healthcare industry, today announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO).
RTO Transaction Proposed Between Hochschild's Tiernan Gold and Railtown Capital; Fausto Di Trapani to Be Named CEO of Resulting Issuer — Neutral
HCHDF MAG Newsfile Corp — September 03, 2025Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Tiernan Gold Corp. ("Tiernan"), a wholly owned subsidiary of Hochschild Mining PLC (LSE: HOC) (OTCQX: HCHDF) ("Hochschild"), which is advancing the large-scale open-pit heap leach Volcan gold project located in the Maricunga Region of Chile (the "Volcan Project" or "Project"), and Railtown Capital Corp. (TSXV: RLT.P) ("Railtown"), a capital pool company, are pleased to announce that they have entered into a letter of intent (the "LOI") dated September 2, 2025. The LOI outlines the general terms and conditions pursuant to which Railtown and Tiernan expect to effect a business combination that …
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 — Neutral
ARQT GlobeNewsWire — September 03, 2025If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to topical steroids and vitamin-D analogs ZORYVE cream is uniquely formulated to be effective, safe, and well tolerated for all areas of the body, including sensitive areas such as intertriginous skin, where plaque psoriasis often presents in children WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental …